A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Insulin (Primary) ; Antihyperglycaemics
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors MannKind Corporation
- 31 Aug 2018 Biomarkers information updated
- 23 Oct 2014 Planned End Date changed from 1 Dec 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 23 Oct 2014 Planned primary completion date changed from 1 Aug 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov.